BIOGRAPHICAL SKETCH NAME POSITION TITLE (Current) Aaron W Michels Assistant Professor of Pediatrics and Medicine eRA COMMONS USER NAME (credential, e.g., agency login) michels.a EDUCATION/TRAINING DEGREE INSTITUTION AND LOCATION YEAR(s) FIELD OF STUDY (if applicable) Creighton University, Omaha, NE B.S. 1997 - 2000 Chemistry Creighton University School of Medicine, Omaha, NE M.D. 2000 - 2004 Medicine University of Nebraska Medical Center, Omaha, NE Residency 2004 - 2007 Internal Medicine University of Colorado Denver, Aurora, CO Fellow 2007 - 2008 Clinical Endocrinology Barbara Davis Center, Aurora, CO Fellow 2008 - 2010 Immunology & Type 1 Diabetes A. Personal Statement I am currently an Assistant Professor in the Departments of Pediatrics and Medicine at the Barbara Davis Center for Diabetes. I also serve as Director of Clinical Immunology at the Center. My professional research career focuses on understanding the underlying immunology of autoimmune disorders with a focus on type 1 diabetes. Having lived with type 1 diabetes for the last twenty-two years, it is my career goal to contribute to the prevention and ultimately a cure for the disease. I have an excellent background in chemistry and immunology. Over the last several years, I have investigated the structural immunology of autoantigen presentation to T cell receptors to understand the role of MHC class II alleles in mediating diabetes risk and protection. Studies are currently being done in collaboration with John Kappler to understand the register of insulin B chain amino acids 9-23 presented by human ‘diabetogenic’ MHC II alleles and subsequent T cell responses to these register trapped peptides. Furthermore, I have used this structural immunology knowledge to develop a novel research area. Under the tutelage of George Eisenbarth, we discovered that small ‘druglike’ molecules targeted to MHC class II antigen presentation can block T cell responses and prevent diabetes onset in spontaneous animal models of autoimmune diabetes. The concept of blocking a specific MHC class II allele is now being tested in a clinical trial with recent onset type 1 diabetes patients (ClinicalTrials.gov NCT01883804). B. Employment: 2004 – 2007 2012 – Present 2012 – Present 2013 – Present Internal Medicine Residency, University of Nebraska Medical Center, Omaha, NE; Board Certified in Internal Medicine Clinical Fellow in Endocrinology, Metabolism, and Diabetes at the University of Colorado Denver, Aurora, CO; Board Certified in Endocrinology, Diabetes, and Metabolism Research Fellow in Endocrinology, Metabolism, and Diabetes at the University of Colorado; research at the Barbara Davis Center for Diabetes mentored by George Eisenbarth MD, Ph.D Assistant Professor, Department of Pediatrics and Medicine, Barbara Davis Center, Aurora, CO; tenure track Director of Clinical Immunology at the Barbara Davis Center Frieda and George S. Eisenbarth Clinical Immunology Endowed Chair Director, CLIA Laboratory at the Barbara Davis Center Honors: 2000 – 2004 2002 Creighton University School of Medicine Scholarship Bernice Shanklin Memorial Scholarship from the Nebraska Medical Association 2007 – 2008 2008 – 2010 2010 – Present 2003 2004 2007 2008 2011 2012 2013 2013 Frank H Tanner, M.D., Scholarship from the Nebraska Medical Foundation Walter J. O’Donohue, Jr., M.D. Achievement Award, Pulmonary/ Critical Care Division Most Outstanding Medical Student of the Year Excellent Oral Presentation by a House Officer at the Midwest Student Biomedical Research Forum O’Brien Physician Scientist Fellowship Award, provided by the Barbara Davis Center for Childhood Diabetes Travel Award to the Federation of Clinical Immunology Annual Meeting Travel Award to the Federation of Clinical Immunology Annual Meeting George S. Eisenbarth Memorial Lecture at the National Institute of Health Travel Award to the American Diabetes Association Annual Meeting C. Selected Peer-reviewed publications (in chronological order from 24 peer-reviewed publications). 1. Michels AW and Eisenbarth GS. Autoimmune Polyendocrine Syndrome Type 1 as a Model for Understanding Autoimmune Polyendocrine Syndrome Type 2. J Internal Medicine. 2009 265:530-40. PMID 19382992. 2. Michels AW and Eisenbarth GS. Immunologic Endocrine Disorders. Journal of Allergy and Clinical Immunology. 2010 Feb; 125:S226-37. PMID: 20176260. 3. Michels AW and Gottlieb PA. Autoimmune Polyglandular Syndromes. Nat Rev, Endocrinol. 2010 6:270-7. PMID 20309000. 4. Michels AW and Nakayama M. The Anti-Insulin Trimolecular Complex in Type 1 Diabetes. Current Opinion in Endocrinology, Diabetes, and Obesity 2010; 17:329-34. PMID: 20489610. 5. Michels AW and von Herrath MG. 2011 Update: antigen specific therapies in type 1 diabetes. Current Opinion in Endocrinology, Diabetes, and Obesity 2011; 18:235-40. PMID: 21844706. 6. Michels AW and Eisenbarth GS. Immune intervention in type 1 diabetes. Seminars in Immunology 2011:23:214-19. PMID 21852151. 7. Crawford F, Stadinski B, Jin N, Michels A, Nakayama M, Pratt P, Marrack P, Eisenbarth G, and Kappler JW. The specificity and detection of insulin reactive CD4+ T cells in type-1 diabetes in the NOD mouse. PNAS 2011 108(40):16729-34. PMID 21949373. 8. Zhang L, Stadinski B, Michels A, Kappler JW, and Eisenbarth GS. Immunization with an insulin peptide –MHC complex to prevent type 1 diabetes of NOD mice. Diabetes Metabolism Research and Reviews 2011 Nov; 27 (8):784-9. PMID: 22069260. 9. Michels AW, Ostrov DA, Zhang L, Nakayama M, Fuse M, Mcdaniel K, Roep BO, Gottlieb PA, Atkinson MA, and Eisenbarth GS. Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. Journal of Immunology 2011 Dec 1; 187(11):5921-30. PMID: 22043012. 10. Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve Cpeptide responses in participants with type 1 diabetes after the new-onset period: a randomized controlled trial. Diabetologia. 2013 Feb; 56(2):391-400. PMID: 23086558. 11. Michels AW. Targeting the Trimolecular Complex: The Pathway Towards Type 1 Diabetes Prevention. Diabetes Technology and Therapeutics 2013 Jun;Suppl 2:S2-12. PMID: 23786298. 12. Gottlieb PA, Delong T, Baker RL, Fitzgerald-Miller L, Wagner R, Cook G, Rewers MR, Michels A, Haskins K. Chromogranin A is a T cell antigen in human type 1 diabetes. J Autoimmun. 2013 Nov; S0896-8411(13)00135-2.PMID: 24239002. 13. Michels AW. Targeting the Trimolecular Complex. Clinical Immunology 2013 Dec;149(3):339-44. PMID: 23537861. 14. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014 Jan 4;383(9911):6982.PMID: 23890997.